Products · Clinical wound healing
Products for every step to healing
Instaqrett and Ynolens are procured in Swedish healthcare regions and are growing. Admercin is the infection control step of the same treatment sequence.
Products
Portfolio range
- Debridement
- Instaqrett®
- Infection
- Admercin™ · PRECLINICAL
- Odour
- NoSmell™ (Ynolens)
- Market
- GLOBAL
- Procured
- SEVERAL SWEDISH REGIONS
The range
One supplier, three products
Debridement
Instaqrett®
Preparing the wound: rapid removal of dead tissue, the first condition for healing.
Odour control
NoSmell™ (Ynolens)
Perfume-free odour control throughout the entire course of treatment.
Infection control
Admercin™
Under development
Peptides that physically destroy resistant bacteria. No resistance observed over 20 generations in vitro.
Legacy
The EPIPROTECT legacy and the ABENA collaboration
EPIPROTECT was developed by S2Medical and is today standard of care for burns at clinics around the world. The product is owned by EPIPROTECT AB, a wholly owned subsidiary of ABENA, with recurring revenue to S2Medical.
- Owner
- EPIPROTECT AB (ABENA)
- Indication
- Burns · partial thickness · donor sites · temporizer for full thickness burns · chronic wounds
- Evidence
- 9+ PEER-REVIEWED PUBLICATIONS
- RCT
- Comparable to porcine xenograft
- Status
- GLOBAL STANDARD OF CARE
For healthcare providers
Procurement and training
Instaqrett and Ynolens are available through procurement agreements in Swedish healthcare regions. We train clinical staff in the use of the products.